Phase Ⅳ study with epristeride,a new type of 5?-reductase inhibitor,on treatment of benign prostatic hyperplasia
- VernacularTitle:新型5?-还原酶抑制剂爱普列特治疗良性前列腺增生的Ⅳ期临床研究
- Author:
Ningchen LI
;
Yanqun NA
;
Qiang DING
- Publication Type:Journal Article
- Keywords:
Androstadienes;
Clinical trial,phase Ⅳ;
Prostatic hyperplasia;
Epristeride
- From:
Chinese Journal of Urology
2001;0(07):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective Study the efficacy and safety of epristeride, a new uncompetitive 5?-reductase inhibitor, in the treatment of benign prostatic hyperplasia(BPH). Methods A multicentral opened clinical trial was conducted. 2 006 BPH patients were enrolled in the trial, in which 5mg epristeride was orally administered twice a day. Results After 4 months therapy, IPSS score was averagely decreased 6.12(28.8%) ( P
